Remove Books Remove Chemotherapy Remove FDA
article thumbnail

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

pharmaphorum

The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown. billion in sales for AZ last year, a rise of around 25%, while Merck booked just under $1 billion from the drug.

FDA 140
article thumbnail

AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1

pharmaphorum

The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, after granting the application a priority review. billion in sales for AZ last year, while Merck booked $725 million from the drug.

FDA 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Libtayo gets a double with EU approvals in skin, lung cancer

pharmaphorum

Sanofi booked €26 million ($31 million) from the drug in the first three months of the year, with Regeneron recording $69 million in sales, although the partners both think that Libtayo as the potential to reach blockbuster revenues.

article thumbnail

Disappointment as Lynparza fails colorectal cancer test

pharmaphorum

They were randomised to either Lynparza alone, Lynparza plus Avastin or chemotherapy plus Avastin, a standard treatment in this setting. billion for AZ last year across its eight FDA-approved indications, while Merck booked $989 million from its share of profits from the drug.

article thumbnail

Uncovering the potential of ADCs to target tumours

European Pharmaceutical Review

1,2 This is especially important in forms of cancer where chemotherapy remains the main treatment option. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy. ASCO Educational Book. References Fu et al.

article thumbnail

Solutions for Constipation Relief

The Thyroid Pharmacist

Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Tenapanor : Tenapanor was approved by the FDA in September of 2019 for IBS-C. [45] As the intestines are made of smooth muscles, a reduction in the action of these muscles can slow down digestion and cause constipation. 2020;12(1):205.